News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Enters Into Development and Commercial Alliance with Maruishi for Novel Kappa Opioid Agonist, CR845, in Japan
Focus on Acute Pain and Uremic Pruritus
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain
- Statistically significant decreases in morphine use and pain intensity demonstrated in 24-hour period after surgery with pre- and post-operative administration of CR845 -
View HTML
Toggle Summary Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation (CKD Pharm) today announced that they have entered into a licensing agreement that provides CKD
View HTML
Toggle Summary Cara Therapeutics Successfully Completes Phase I Study With Oral Formulation of Its Novel Kappa Opioid Receptor Agonist, CR845
- robust bioavailability and pharmacologic activity seen with oral formulation of peptide-based Kappa Opioid Agonist -
View HTML
Toggle Summary Cara Therapeutics Initiates Phase II Trial of Novel Analgesic In Acute Post-Operative Pain
Peripherally-Acting Kappa Opioid Agonist, CR845, to Be Studied in Both Pre- and Post-Operatove Drug Regimens
View HTML
Toggle Summary Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today)
Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...
View HTML
Toggle Summary Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
CR845, a novel, peripherally restricted kappa opioid agonist, is currently in Phase 2 development for treatment of post-operative pain
View HTML
Toggle Summary Cara's No-Brainer Opioid Solution
Cara's No-Brainer Opioid Solution San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side
View HTML
Toggle Summary Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain
Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa
View HTML
Toggle Summary Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist,
View HTML